FDA Approved: PARSABIV — Original Application (Amgen, Inc)

View source ↗

Summary

FDA approved PARSABIV (etelcalcetide) in an Original Application (NDA 208325) by Amgen, Inc for the treatment of secondary hyperparathyroidism in adults on main…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• Parsabiv (etelcalcetide)

Snippet

ORIG AP for PARSABIV (ETELCALCETIDE)